Abstract: Systems and methods for diagnosing a condition in an individual by analyzing the individual's breath are provided. Sensors may be configured to capture data associated with the breath of an individual. The data captured by the sensors may include a change in resistance measurements recorded by solid-state sensors when the sensors are exposed to the individual's breath at several different temperatures. This captured data may be analyzed to identify one or more volatile organic compound (VOC) biomarkers in the individual's breath. Based on the identified VOC biomarkers, a condition associated with the individual may be determined. For example, a medical condition, or a condition of drowsiness or fatigue associated with the individual may be determined based on the VOC biomarkers in the individual's breath. In some examples, the sensors may be positioned inside a vehicle for determination of condition associated with a driver of the vehicle.

Abstract: Provided herein are methods implemented by a processor in a computer for designing a clamp peptide comprising the structure A1-B-A2 wherein A1 is a first peptide arm that binds to a first binding site of a target protein, A2 is a second peptide arm that binds to a second binding site of the target protein, and B is a bridge peptide which links A1 to A2. Also provided herein are computer-readable storage media having stored thereon machine-readable instructions executable by a processor and systems. Related methods of manufacturing a clamp peptide and the clamp peptides manufactures by the methods are provided.

Abstract: Disclosed herein are topical formulations of cannabidiol, such as nanoparticulate cannabidiol, methods of making such compositions, and their use in treating autoimmune diseases and disorders, e.g., alopecia areata.

Abstract: This disclosure relates to systems, compounds and methods for stem cell delivery. More specifically, the disclosure relates a system for promoting tissue regeneration, the system comprising a plurality of stem cells coated with at least one or a plurality of dendrimer nanocarriers that specifically bind to an adhesion molecule. Additionally, the disclosure relates to methods for delivering stem cells to damaged or diseased tissue for stem cell regeneration of the tissue.

Abstract: Kits and methods for detecting pathogens without the need for laboratory equipment are disclosed. The kits and methods described herein allow for near-room temperature amplification of pathogen polynucleotides in a biological sample in a one-compartment reaction vessel. The kits and methods may be used to detect any target nucleic acid, such as DNA or RNA from a bacterial, fungal, or viral pathogen.

Abstract: Provided herein are Zika virus (ZIKV) binding constructs, e.g., antibodies and antigen-binding fragments thereof and antibody mimetics, as well as related conjugates, polypeptides, nucleic acids, expression vectors, host cells, kits, and assay systems. Methods detecting ZIKV infection and/or ZIKV exposure and/or ZIKV immunity are provided.

Abstract: The disclosure relates to test kits and methods for detecting the presence of Coronavirus polynucleotides in a biological sample.

Abstract: Systems and methods for diagnosing a condition in an individual by analyzing the individual's breath are provided. Sensors may be configured to capture data associated with the breath of an individual. The data captured by the sensors may include a change in resistance measurements recorded by solid-state sensors when the sensors are exposed to the individual's breath at several different temperatures. This captured data may be analyzed to identify one or more volatile organic compound (VOC) biomarkers in the individual's breath. Based on the identified VOC biomarkers, a condition associated with the individual may be determined. For example, a medical condition, or a condition of drowsiness or fatigue associated with the individual may be determined based on the VOC biomarkers in the individual's breath. In some examples, the sensors may be positioned inside a vehicle for determination of condition associated with a driver of the vehicle.

Abstract: Kits and methods for detecting pathogens without the need for laboratory equipment are disclosed. The kits and methods described herein allow for near-room temperature amplification of pathogen polynucleotides in a biological sample in a one-compartment reaction vessel. The kits and methods may be used to detect any target nucleic acid, such as DNA or RNA from a bacterial, fungal, or viral pathogen.

Abstract: The disclosure relates to test kits and methods for detecting the presence of Coronavirus polynucleotides in a biological sample.

Abstract: Provided herein are methods implemented by a processor in a computer for designing a clamp peptide comprising the structure A1-B-A2 wherein A1 is a first peptide arm that binds to a first binding site of a target protein, A2 is a second peptide arm that binds to a second binding site of the target protein, and B is a bridge peptide which links A1 to A2. Also provided herein are computer-readable storage media having stored thereon machine-readable instructions executable by a processor and systems. Related methods of manufacturing a clamp peptide and the clamp peptides manufactures by the methods are provided.

Abstract: Provided herein are Zika virus (ZIKV) binding constructs, e.g., antibodies and antigen-binding fragments thereof and antibody mimetics, as well as related conjugates, polypeptides, nucleic acids, expression vectors, host cells, kits, and assay systems. Methods detecting ZIKV infection and/or ZIKV exposure and/or ZIKV immunity are provided.

Abstract: The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.

Abstract: The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.

Abstract: The presently-disclosed subject matter provides systems, methods, and kits for diagnosing and/or monitoring a bacteria-related condition of interest in a subject by providing a cell sensing system, each system containing a reporter molecule capable of detecting binding of a quorum sensing molecule and capable of generating a detectable signal.

Abstract: The presently-disclosed subject matter is directed to biosensors comprising spore-forming bacterial cells and/or spores generated therefrom, a recognition unit within each spore-forming cell for binding an analyte of interest, and a reporter molecule within each spore-forming cell for detecting binding of the analyte of interest, wherein the reporter molecule generates a detectable signal upon binding of the analyte by the recognition element. The presently-disclosed subject matter further provides methods of using the biosensors and systems and kits including the biosensors.

Abstract: The presently-disclosed subject matter is directed to biosensors comprising spore-forming bacterial cells and/or spores generated therefrom, a recognition unit within each spore-forming cell for binding an analyte of interest, and a reporter molecule within each spore-forming cell for detecting binding of the analyte of interest, wherein the reporter molecule generates a detectable signal upon binding of the analyte by the recognition element. The presently-disclosed subject matter further provides methods of using the biosensors and systems and kits including the biosensors.

Abstract: The presently-disclosed subject matter provides systems, methods, and kits for diagnosing and/or monitoring a bacteria-related condition of interest in a subject by providing a cell sensing system, each system containing a reporter molecule capable of detecting binding of a quorum sensing molecule and capable of generating a detectable signal.

Abstract: A solid-phase immunoassay for 6-keto-Prostaglandin F1?, the stable hydrolysis product of prostacyclin (Prostaglandin I2) is disclosed. Prostacyclin, a potent vasodilator with anti-platelet and anti-proliferative properties is an effective treatment for primary pulmonary hypertension and pulmonary arterial hypertension associated with scleroderma and scleroderma-like syndrome. Levels of 6-keto-Prostaglandin F1? can be directly correlated with levels of prostacyclin. Therefore, 6-keto-Prostaglandin F1? has become the indicator of choice to measure prostacyclin levels. The single step immunoassay for 6-keto-Prostaglandin F1? uses the bioluminescent protein, aequorin as a label. Analyte-label conjugates were constructed by linking the carboxyl group of 6-keto-Prostaglandin F1? and lysine residues of aequorin by chemical conjugation methods. The binding properties of 6-keto-Prostaglandin F1? towards its antibody and the bioluminescent properties of aequorin are retained in the conjugate.